Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CSPC Pharmaceutical Group Ltd (CSPC) carries out the research, development, manufacture, and sale of pharmaceutical products. The company's product portfolio includes treatments for nervous system diseases, respiratory disease, diabetes, oncology, anti-infective, and cardiovascular diseases. It also offers Vitamin C, antibiotics and caffeine products. CSPC offers its products under the brands NBP, Domeisu, Gubang, Gubangjia, Gaoshunsong, Jinyouli, Keaili, and Xuanning, among others The company offers its products to healthcare providers and patients across various therapeutic areas. It has operations across the US, China, Hong Kong and Germany. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
Headquarters
China
Address
No.896 Zhongshandong Street, Shijiazhuang, Hebei, 050035
Website
www.cspc.com.hk
Telephone
86 311 87037015
No of Employees
18,626
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1093 (HKG)
Revenue (2024)
$3.6B
-10.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-10.3%
(2024 vs 2023)
Market Cap*
$11.8B
Net Profit Margin (2024)
XYZ
0.1%
(2024 vs 2023)
* As of and is in US$
CSPC Pharmaceutical Group Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Nervous System Disease Products | Oulaining |
| Oncology Products | Enxi |
| Anti-infective Products | NBP |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In October, the company secured approval from the National Medical Products Administration of the People’s Republic of China for SYS6062 to conduct clinical trials in China. |
| 2026 | Regulatory Approval | In October, the company secured approval from the National Medical Products Administration to conduct clinical trials for SYS 6088, a recombinant humanized trispecific antibody targeting PD‑1, VEGFA and CTLA‑4 for anti-tumor therapy. |
| 2026 | New Products/Services | In October, the company launched the Phase I clinical trial (SYS 6077-001) of the group’s SYS 6077 injection for the treatment of advanced malignant tumors. |
Competitor Comparison
| Key Parameters | CSPC Pharmaceutical Group Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Sino Biopharmaceutical Ltd | Zhejiang Medicine Co Ltd | China Medical System Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | Hong Kong |
| City | Shijiazhuang | Shanghai | Hong Kong City | Shaoxing | Hong Kong City |
| State/Province | Hebei | Shanghai | - | Zhejiang | - |
| No. of Employees | 18,626 | 40,603 | 22,838 | 5,417 | 6,415 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| CAI Dong Chen | Chairman | Executive Board | 1997 | 72 |
| Cai Lei | Chief Executive Officer; Vice Chairman | Executive Board | 2025 | 46 |
| Wei Qingjie | Vice Chairman | Executive Board | 2025 | 56 |
| Cai Xin | Director | Executive Board | 2024 | 34 |
| QU Zhiyong | Director | Executive Board | 2025 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer